Ben Tre Pharmaceutical JSC (STC:DBT) Cash Flow from Financing: ₫0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:DBT Ben Tre Pharmaceutical JSC STC:DBT
13 GF Score
Price ₫12,500.00
! 1 Warning Sign
View Full Analysis

What is Ben Tre Pharmaceutical JSC Cash Flow from Financing?

Ben Tre Pharmaceutical JSC STC:DBT -0.79% 13 Cash Flow from Financing is ₫0.00 Mil as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in . 20, Ben Tre Pharmaceutical JSC paid ₫0.00 Mil more to buy back shares than it received from issuing new shares. It received ₫0.00 Mil from issuing more debt. It paid ₫0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received ₫0.00 Mil from paying cash dividends to shareholders. It received ₫0.00 Mil on other financial activities. In all, Ben Tre Pharmaceutical JSC spent ₫0.00 Mil on financial activities for the six months ended in . 20.


Ben Tre Pharmaceutical JSC  (STC:DBT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Ben Tre Pharmaceutical JSC's issuance of stock for the six months ended in . 20 was ₫0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Ben Tre Pharmaceutical JSC's repurchase of stock for the six months ended in . 20 was ₫0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Ben Tre Pharmaceutical JSC's net issuance of debt for the six months ended in . 20 was ₫0.00 Mil. Ben Tre Pharmaceutical JSC received ₫0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Ben Tre Pharmaceutical JSC's net issuance of preferred for the six months ended in . 20 was ₫0.00 Mil. Ben Tre Pharmaceutical JSC paid ₫0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Ben Tre Pharmaceutical JSC's cash flow for dividends for the six months ended in . 20 was ₫0.00 Mil. Ben Tre Pharmaceutical JSC received ₫0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Ben Tre Pharmaceutical JSC's other financing for the six months ended in . 20 was ₫0.00 Mil. Ben Tre Pharmaceutical JSC received ₫0.00 Mil on other financial activities.


Ben Tre Pharmaceutical JSC Cash Flow from Financing Related Terms


Ben Tre Pharmaceutical JSC Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Ben Tre Pharmaceutical JSC's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ben Tre Pharmaceutical JSC Cash Flow from Financing Chart

Ben Tre Pharmaceutical JSC Annual Data
Trend
Cash Flow from Financing

Ben Tre Pharmaceutical JSC Semi-Annual Data
Cash Flow from Financing
STC:DBT
13GF Score
Ben Tre Pharmaceutical JSC STC:DBT
Cash Flow from Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ben Tre Pharmaceutical JSC Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Ben Tre Pharmaceutical JSC's Cash from Financing for the fiscal year that ended in . 20 is calculated as:

Ben Tre Pharmaceutical JSC's Cash from Financing for the quarter that ended in . 20 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in . 20 was ₫0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of ₫0.00 Mil mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a Cash Flow from Financing of ₫0.00 Mil as of . 20. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Ben Tre Pharmaceutical JSC and its competitors.
Is Ben Tre Pharmaceutical JSC's Cash Flow from Financing too high?
Ben Tre Pharmaceutical JSC's current Cash Flow from Financing is ₫0.00 Mil. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's Cash Flow from Financing compare to ZTS and UTHR?
Ben Tre Pharmaceutical JSC's Cash Flow from Financing of ₫0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Ben Tre Pharmaceutical JSC and its competitors. Ben Tre Pharmaceutical JSC's current Cash Flow from Financing is ₫0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current Cash Flow from Financing of ₫0.00 Mil. The current Cash Flow from Financing is ₫0.00 Mil. Ben Tre Pharmaceutical JSC's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current Cash Flow from Financing is ₫0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ben Tre Pharmaceutical JSC Business Description

Address No. 6A3, National Highway 60, Phu Tan Ward, Vinh Long Province, Ben Tre, VNM
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
13GF Score

Get the complete analysis for STC:DBT

Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫12,500.00
Price